Table 1

Lipid species altered in concentration in 3T3-L1 adipocytes treated with either the PPARδ agonist GW610742 or the PPARγ agonist GW347845

PPARδ

PPARγ

Increased

Decreased

Increased

Decreased

PC 32:0 (16:0/16:0)

TAG 52:1

TAG 48:0

TAG 44:2

PC 34:0

TAG 52:5

TAG 50:1

TAG 44:1 (15:0/15:0/14:1)

PC 34:1

TAG 52:6

TAG 52:4

TAG 44:1 (15:1/14:0/15:0)

PC 35:5

TAG 53:2

TAG 54:6

TAG 45:2

PC 36:1

TAG (18:3/17:0/19:0)

TAG 54:5

TAG 46:2

PC 36:2

TAG (18:1/17:1/19:1)

TAG 54:4

TAG 47:2

PC 36:3

TAG (20:1/17:1/17:1)

TAG 47:3

TAG (20:1/15:0/19:2)

TAG 48:3

TAG (20:1/15:1/19:1)

TAG 48:2

TAG 49:3

TAG 50:3

Species were detected using LC-MS. Lipids identified in the VIP/coefficient plots as significantly contributing to separation in the principal components analysis (PCA) and PLS-DA models built for the LC-MS analysis of the organic metabolite fraction (P < 0.05 for significant contribution to the first component of the PLS-DA plot). The control group (n = 6) was compared with the PPARδ agonist-treated group (n = 6) or PPARγ agonist-treated group (n = 6). All triacylglycerols (TAGs) were observed as ammonium adducts. Where stated, exact composition was confirmed by tandem mass spectrometry (MS/MS) and phosphocholines (PCs) were identified by monitoring for the loss of the choline head group during MS/MS.

Roberts et al. Genome Biology 2011 12:R75   doi:10.1186/gb-2011-12-8-r75